Agios Pharmaceuticals Inc. Common Stock (AGIO)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Agios as a Graham-style analyst, asking what is proven and what is hope. Its business is developing cellular-metabolism medicines, led by PYRUKYND for hemolytic anemias. The commercial trend is encouraging: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $44.7 million versus $12.5 million in fiscal Q2 2025, the quarter ended 2025-06-30, while the net loss narrowed to $100.7 million, or $1.69 per diluted share, from $112.0 million, or $1.93 per diluted share. Still, the company lost $412.8 million in fiscal 2025, or $7.12 per diluted share, after fiscal 2024 net income of $673.7 million, or $11.64 per diluted share. That swing, and the FairStock TURNAROUND label - loss in the latest year after earlier profits - tells me the numbers are not yet dependable.

In plain English: Agios makes medicines for blood disorders, mainly a drug called PYRUKYND. Sales are growing, but the company still loses a lot of money and spends more cash than it brings in. At the recent price, the shares look more like a bet on future medical success than a clear bargain based on today's profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer